As of 2024-12-14, the Intrinsic Value of Nuvo Pharmaceuticals Inc (MRV.TO) is
11.85 CAD. This MRV.TO valuation is based on the model Discounted Cash Flows (Growth Exit 10Y).
With the current market price of 1.35 CAD, the upside of Nuvo Pharmaceuticals Inc is
778.10%.
The range of the Intrinsic Value is 3.83 - 97.55 CAD
11.85 CAD
Intrinsic Value
MRV.TO Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(5.60) - 1.58 |
(4.99) |
-469.6% |
| DCF (Growth 10y) |
3.83 - 97.55 |
11.85 |
778.1% |
| DCF (EBITDA 5y) |
(3.55) - (1.40) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(0.16) - 4.00 |
1.14 |
-15.5% |
| Fair Value |
6.65 - 6.65 |
6.65 |
392.82% |
| P/E |
9.31 - 20.25 |
14.20 |
952.2% |
| EV/EBITDA |
1.61 - 22.03 |
10.28 |
661.8% |
| EPV |
34.27 - 37.89 |
36.08 |
2572.7% |
| DDM - Stable |
13.41 - 432.23 |
222.82 |
16405.3% |
| DDM - Multi |
(31.32) - (818.45) |
(61.46) |
-4652.5% |
MRV.TO Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
15.39 |
| Beta |
0.83 |
| Outstanding shares (mil) |
11.40 |
| Enterprise Value (mil) |
83.45 |
| Market risk premium |
5.10% |
| Cost of Equity |
7.61% |
| Cost of Debt |
5.37% |
| WACC |
5.49% |